Results from the longest-running trial of semaglutide—the active ingredient in the popular drugs Ozempic and Wegovy—are in, and the verdict is decidedly positive. The study found that people taking semaglutide tended to maintain their initial weight loss for up to four years. Other trial data presented this week also suggests that semaglutide can improve people’s heart health even without causing weight loss .
And not everyone taking the drug in the trial lost significant weight or necessarily maintained their weight loss four years later. But the data does indicate that semaglutide and other related GLP-1 drugs generally can be taken over the long haul without losing their potency or causing serious problems. GLP-1 drugs are known to cause common gastrointestinal side effects such as vomiting and diarrhea, though some data has suggested that these side effects become less common over time.
Source: Law Daily Report (lawdailyreport.net)
Weight Loss Health Medical Pharma GLP-1 Receptor Agonist Semaglutide John Deanfield Obesity Cardiovascular Disease Glucagon-Like Peptide-1 Peptide Therapeutics Novo Nordisk Diabetes Peptide Hormones Cagrilintide/Semaglutide Gizmodo
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: CNBC - 🏆 12. / 72 Read more »
Source: nbcsandiego - 🏆 524. / 51 Read more »
Source: futurism - 🏆 85. / 68 Read more »
Source: FoxBusiness - 🏆 458. / 53 Read more »
Source: LDNfashion - 🏆 157. / 63 Read more »
Source: NPR - 🏆 96. / 63 Read more »